iBET participates in 3rd Annual Meeting of ADDovenom Project

On September 12-13th, António Roldão and Raquel Garcia from the Cell-Based Vaccines Development Lab at iBET, participated in the 3rd annual meeting of the ADDovenom project, held in Liverpool, UK.

ADDovenom’s main goal is to develop a novel snakebite therapy of unparalleled efficacy, safety, and affordability against the most prevalent Sub-Saharan snakes.

To achieve this, the project leverages an innovative platform consisting of a protein-based nanoscaffold known as ADDomer© - a thermostable synthetic virus-like particle with 60 binding sites that are engineered to neutralize and eliminate venom toxins from the bloodstream.

During this year’s event, organized by the Liverpool School of Tropical Medicine (LSTM), all participating partners had the opportunity to tour the LSTM herpetarium and gain further insights into the extraction of snake venom.

Raquel Garcia delivered a presentation detailing iBET’s ongoing efforts to optimize the ADDomer purification strategy. The objective is to establish a scalable, cost-efficient, and GMP-compliant purification process.

ADDovenom is an EU-funded project under the H2020 program, with coordination by the University of Bristol and collaboration from partners at University of Liège, Aix-Marseille University, Liverpool School of Tropical Medicine and iBET.

The project is scheduled to be completed in 2024 with a 4th and final annual meeting that will take place at iBET.

For more information about the ADDovenom project, please visit the provided link.